Literature DB >> 9501881

Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis.

J R Smith1, P H Hart, D J Coster, K A Williams.   

Abstract

PURPOSE: To investigate the roles of tumor necrosis factor-alpha (TNF-alpha), interleukin-4 (IL-4), and inducible nitric oxide synthase (iNOS) in endotoxin-induced uveitis (EIU) using gene knock-out mice.
METHODS: Mice (C57BL/6 x 129) either of normal phenotype or deficient in the genes encoding one or both tumor necrosis factor receptors (TNFR p55 and TNFR p75), IL-4, or iNOS were given footpad injections of 400 micrograms Escherichia coli lipopolysaccharide. Animals were killed 24 hours later, and infiltrating cells were counted on 5-micron ocular cross-sections through the optic nerve.
RESULTS: All abnormal mouse phenotypes were susceptible to EIU. Yet, TNFR p55 and IL-4 gene knock-out mice experienced less ocular inflammation than control animals (P = 0.021 and 0.007, respectively), whereas disease was not reduced for iNOS-deficient mice. Mice deficient in TNFR p55 and TNFR p75 experienced milder EIU than mice lacking TNFR p75 alone (P = 0.046).
CONCLUSIONS: Mice deficient in TNFR p55 and TNFR p75, IL-4, or iNOS retain the susceptibility to EIU, but TNF-alpha and IL-4 influence the influx of inflammatory cells to the eye during this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9501881

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Apoptosis is a prominent feature of acute anterior uveitis in the Fischer 344 rat.

Authors:  J R Smith; P H Hart; S D Standfield; D J Coster; S J Wing; K A Williams
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

3.  Impact of IL-1 signalling on experimental uveitis and arthritis.

Authors:  Stephen R Planck; April Woods; Jenna S Clowers; Martin J Nicklin; James T Rosenbaum; Holly L Rosenzweig
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

Review 4.  Management of uveitis in pediatric patients: special considerations.

Authors:  Justine R Smith
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Anti-inflammatory effects of specific cyclooxygenase 2,5-lipoxygenase, and inducible nitric oxide synthase inhibitors on experimental autoimmune anterior uveitis (EAAU).

Authors:  Nalini S Bora; Jeong-Hyeon Sohn; Puran S Bora; Henry J Kaplan; Prasad Kulkarni
Journal:  Ocul Immunol Inflamm       Date:  2005 Apr-Jun       Impact factor: 3.070

6.  Interleukin-1 receptor signaling rather than that of tumor necrosis factor is critical in protecting the host from the severe consequences of a polymicrobe anaerobic infection.

Authors:  D T Graves; C P Chen; C Douville; Y Jiang
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

Review 7.  [TNFalpha inhibitors in the treatment of uveitis].

Authors:  K Greiner; J Plskova
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

8.  Susceptibility to endotoxin induced uveitis is not reduced in mice deficient in BLT1, the high affinity leukotriene B4 receptor.

Authors:  J R Smith; K Subbarao; D T Franc; B Haribabu; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

Review 9.  Clinical trials in pediatric uveitis.

Authors:  Lucila M A Agle; Liza B Vazquez-Cobian; Thomas J A Lehman
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

10.  A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).

Authors:  Athimalaipet V Ramanan; Andrew D Dick; Diana Benton; Sandrine Compeyrot-Lacassagne; Dalia Dawoud; Ben Hardwick; Helen Hickey; Dyfrig Hughes; Ashley Jones; Patricia Woo; Clive Edelsten; Michael W Beresford
Journal:  Trials       Date:  2014-01-09       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.